Numerous clinical studies have established that angiotensin II receptor blockers are effective as antihypertensive therapy and are well tolerated. Studies demonstrate that adding an angiotensin II ...

According to Novartis, Entresto is the first and only angiotensin receptor-neprilysin inhibitor (ARNi) currently FDA-approved for use in the US for the treatment of heart failure and has no ...